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F
or 20 years Intuitive Sur-
gical’s da Vinci® system 
has held the monopoly in 
minimally invasive robot-
ic surgery. Restrictive patenting, a 
well-developed marketing strategy and 
a high-quality product have protected 
the company’s leading market share.1 
However, owing to the nuances of 
US patenting law, many of Intuitive 
Surgical’s earliest patents will be 
expiring in the next couple of years. 
With such a shift in backdrop, many 
of Intuitive Surgical’s competitors 
(from medical and industrial robotic 
backgrounds) have initiated robotic 
programmes – some of which are 
available for clinical use now. The next 
section of the review will focus on new 
and developing robotic systems in 
the field of minimally invasive surgery 
(Table 1), single-site surgery (Table 2), 
natural orifice transluminal endoscop-
ic surgery (NOTES) and non-minimally 
invasive robotic systems (Table 3). 
Novel and developmental 
systems in minimally 
invasive surgery
Senhance Surgical Robotic System
TransEnterix’s (US) Senhance Surgical 
Robotic System (Fig 1), which was orig-
inally developed by the robotic division 
of Italian healthcare company SOFAR 
(Italy) and formerly branded the Telelap 
ALF-X, represents the only competi-
tion to the da Vinci® system that has 
both CE approval for use in Europe 
and FDA approval. The distinguishing 
features of this system include an open 
remote control console capable of 
3D-HD through use of 3D glasses, an 
eye-tracking system for camera control, 
three laparoscopic robotic arms on 
separate carts (as opposed the single 
cart seen in the da Vinci® system), 
laparoscopic handles with six degrees 
of freedom to control laparoscopic 
robotic instruments and, most impres-
sively, haptic force feedback to the 
surgeon provided through the laparo-
scopic handles.2 In Europe the system 
is licensed for use in abdominal, pelvic 
and thoracic procedures, excluding 
cardiac surgery. To date clinical trials 
have shown the Senhance system to 
be safe and efficacious in minimally in-
vasive surgery. However, trials are from 
a single centre, involve small patient 
numbers and include only gynaeco-
logical and colorectal procedures.3,4 
Animal studies have been successfully 
conducted in porcine partial nephrecto-
my and bovine pulmonary lobectomy.2,5
How robotics could help shape the  
future of surgical care
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Device Developer Special features Clinical use
Telelap ALF-X/Senhance 
surgical system
TransEntrix  Inc. (Morrisville, US) 3 separate cart mounted robotic arms, 
3D-HD ready with glasses laparoscopic 
handles with haptic force feedback, 
eye-tracking camera
CE approval 2006, FDA approval 
2017, gynaecology, colorectal, 
limited cardiothoracics
Versius CMR Surgical (UK) 5 light weight portable separate cart 
mounted robotic arms, 3D HD ready 
monitor with glasses, haptic feedback
Cadaveric and animal studies, 
anticipated CE approval in 2018. 
Gynaecology, upper GI, renal, 
colorectal.
MiroSure Medtronic (Dublin, Ireland),  
DLR (Germany)
3–5 lightweight arms attached to 
operating table, impedance mode, 
Autopointer, 3D-HD ready with 3D 
glasses, haptic feedback
Development stage, no FDA/CE 
approval, minimally invasive surgery
REVO-I Meere Company (South Korea) 4 robotic arms with single Cart, open 
3D/HD control console
Korean ministry of food and drug 
safety approval 2017. human trials 
underway, gynaecology, urology, 
general surgery
M7 Telerobotic surgical system/
Verb Surgical
Stanford Research International 
Robotics. Licencing from Verb 
Surgical
2 lightweight robotic arms (15kg) with 7 
d.o.f., auditory, visual, tactile feedback.  
Motion compensation
In development, no FDA/CE 
approval, minimally invasive surgery
Table 1 Novel robotic systems in minimally invasive surgery
Device Developer Features Clinical use
SurgiBot Transenterix (US) Bedside control unit, 3D-HD ready with 3D 
glasses
Single port MIS, FDA rejected, seeking CFDA 
approval
da Vinci® SP1098 
platformw
Intuitive Surgical (US) 3D HD ready articulated camera, 25mm access 
port, compatible with da Vinci® Xi side cart
Single port minimally invasive surgery, no FDA/
CE approval, human pre-clinical studies
SPORT Titan medical (US) Open console, 3D/HD ready, 25mm single port Single port minimally invasive surgery, no FDA/
CE approval, pre-clinical trials underway
MIVR Virtual Incision (US) 2 robotic arms, miniaturised motor units 
housed within the arms themselves, reduced 
extracorporeal footprint
Single port minimally invasive surgery No FDA/
CE approval, human trials conducted
MASTER EndoMaster Pte LTD 2 robotic arms incorporated in to videoscope/
endoscope, haptic feedback, grasper and 
electrocautery function
NOTES no FDA/CE approval, human clinical 
trials 2012
Table 2 Robotic systems in single port surgery and natural orifice transluminal endoscopic surgery (NOTES)
Device Developer Features Clinical use
Avicenna Roboflex ELMED (Turkey) Robotic FURS hand piece manipulator, 
open surgeon console, increased 
deflexion range
Retrograde intrarenal surgery, CE 
approval, human trials, FDA approval 
pending
Medical Microinstruments Medical Microinstruments 
(Italy)
World’s smallest robotic articulating 
wrist, 3mm outer diameter
Microsurgery, preclinical trials underway
Preceyes surgical system Preceyes BV (Eindenhoven, 
Holland)
Single robotic bedside arm capable of 
<10micron precision, Intuitive bedside 
control unit 
Vitreoretinal eye surgery, human trials 
underway, no FDA/CE approval
Table 3 Novel non-minimally invasive robotic systems
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Versius
Versius (Fig 2) is developed by the 
UK-based CMR Surgical and is de-
signed for use in gynaecology, upper 
GI surgery, colorectal and urology. 
The system consists of an open 
control console with 3D-HD monitor 
necessitating 3D glasses and up to 5 
collaborative lightweight individually 
mounted robotic arms controlled at an 
open control console providing haptic 
feedback to the operating surgeon. 
There is a strong focus on the light-
weight compact nature of the robotic 
arms, which provides seven degrees 
of freedom and allows for easy set-up 
and portability across theatres. At 
present preliminary animal studies and 
cadaveric trials have taken place; how-
ever, the company is anticipated to file 
for approval for clinical use in 2018.6
MiroSure
MiroSure (Fig 3) stemmed from 
research into telesurgery onboard 
spacecraft and was developed by 
the Robotic and Mechatronic wing 
of the German Aerospace Centre 
(DLR).7 The licence for commercial 
use of MiroSure was sold to Medtronic 
(Dublin, Ireland) in 2013. Medtronic 
are currently developing a new device 
incorporating many of the elements of 
MiroSure. The key features of Miro-
Sure system include up to five mini-
mally invasive robot-assisted (MIRO) 
arms that, unlike the other systems 
described, can attach to the operating 
table rails and represent an interesting 
development allowing operating table 
repositioning without robot undocking 
or interrupting the surgery. Each MIRO 
arm weighs 10kg, provides 7 degrees 
freedom of movement and uses a 
variety of laparoscopic instruments. 
The system contains a 3D-HD monitor 
with 3D glasses and the control mech-
Figure 1 Senhance Surgical system – Single robotic arm units and open control 
system. (Image credit TransEnterix Surgical Inc) 
Figure 2 Versius surgical system. (Image credit CMR Surgical) 
A B
Figure 3 MiroSure robotic system a) Table-mounted robotic arms b) Open 3D-HD 
control console. (Image credit DLR, CC-BY 3.0)
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anism provides haptic feedback. This 
system contains some truly unique 
features. First, the MIRO arms contain 
an ‘impedance-controlled mode’ 
whereby the assistant can reposition 
the robotic arms without altering the 
position and orientation of the end 
effecter, which enables surgery to con-
tinue uninterrupted and allows quick 
access to the patient.8 Second, an 
AutoPointer is included that projects 
an image onto the patient to guide 
optimal port placement for efficient 
kinematics and collision avoidance.9 
DLR’s ultimate aim is to operate on the 
beating heart, with motion compensa-
tion providing automatic co-ordination 
of end effectors in synchronicity with 
systole/diastole providing the surgeon 
with a static image of the heart. This 
feature remains in the early research 
stage but demonstrates an interesting 
future application of MiroSure. Cur-
rently Medtronic are developing their 
tenth prototype and the robotic system 
is expected to launch in India first, 
followed by the US in 2018. There is 
currently no FDA/CE approval in place.
REVO-I
The MSR-5000 REVO-I Robotic 
Surgical System was developed by 
South Korean Meere Company and 
introduced in 2015.10 The system in-
cludes an open 3D-HD control system 
requiring 3D glasses and a 4-arm 
single mounted cart that is analogous 
in layout to that of the da Vinci® SI. 
Currently there is no haptic feedback 
but it is reported that Meere Company 
are integrating this technology in their 
newest model.11 To date, more than 
20 pre-clinical animal studies have 
been conducted with the Revo-I and 
the South Korean Ministry of Food and 
Drug Safety granted approval in August 
2017 for use in human clinical trials.
Verb Surgical
Verb Surgical was founded in 2015 
from a collaboration between Ethicon 
Endo-Surgery (a division of Johnson & 
Johnson) and Verily (formerly Google 
Life sciences). The company remains 
secretive about their future robotic 
system. However, their goal is both 
public and lofty, ie to create ‘Surgery 
4.0’, which transcends the current 
paradigm of master–slave   surgery 
and incorporates increased robotic 
autonomy and machine learning.12 
Verb Surgical is licensing robotic 
technology from Stanford Research 
International Robotics (SRI), which 
began development of the M 7 
Telerobotic surgical system back in 
1998. The key features of this system 
include 2 robotic arms with 7 degrees 
of freedom, a lightweight system 
weighing 15kg, visual, auditory and 
tactile feedback to the surgeon, and 
compensation for external movements 
such as those caused by turbulence 
on a plane or moving vehicle.13 This 
system was principally developed for 
long-distance telesurgery (particularly 
in the battlefield) and trials have been 
conducted both 60 feet underwater 
and on-board the NASA C-9 aircraft, 
simulating surgery in zero gravity. Verb 
Surgical’s future system is shroud-
ed in corporate secrecy but, given 
the considerable financial backing 
and expertise from the companies 
involved, the potential is exciting. We 
currently lack specific details but 
Verb’s upcoming system may incor-
porate technology from SRI’s M 7 
surgical system.
Single-port surgery
Robotic laparo-endoscopic single site 
(R-LESS) surgery aims to improve 
upon the benefits of conventional 
multiport robotic surgery by decreas-
ing the number of surgical incisions 
leading to improved cosmesis; 
reduced recovery time, reduction in 
postoperative pain and decreased 
postoperative incisional herni.14 There 
are disadvantages to decreasing the 
number of ports in use – principally 
poor ergonomics, loss of triangu-
lation, instrument clashing, limited 
tissue retraction and lack of space 
for surgical assistant.15 To date, the 
experience of R-LESS has involved 
modification of existing robotic sys-
tems for use with single-access ports, 
specialised instruments such as 
Intuitive Surgical’s semi-rigid curved 
VeSPA instruments, and development 
of new software for left–right con-
trol swapping to negate issues with 
triangulation.14 These modifications 
compromise on the functionality of 
the robotic systems. However, there 
are several purpose-built single-site 
robotic systems in development and 
these are discussed in the next sec-
tion (Table 2).
da Vinci® SP 1098 surgical system
The Intuitive Surgical da Vinci® 
SP 1098 platform (Fig 4) has been 
developed specifically for use in 
R-LESS since 2014. The system’s 
unique features include access 
through a 25mm single port; intro-
duction of 3 6mm articulated arms 
with surgical instrument end effec-
tors; 8mm articulating 3D-HD cam-
era; slim-lined single-arm platform 
compatible with da Vinci® Xi side 
cart; and a new clutch system on the 
control console to enable control of 
the articulating instruments separate 
to control of the platform single arm. 
Of vital importance is the re-introduc-
tion of Intuitive Surgical’s endo-wrist 
technology, which was lost in the 
VeSPA instruments, and an extra 
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‘elbow-joint’ allowing the instrument 
to ‘fan out’ once through the port, re-
producing the conventional multi-port 
robotic set-up.15 Although Intuitive 
Surgical gained FDA approval for sin-
gle-port surgery in urology in 2014, it 
decided not to market and instead fo-
cus on developing the purpose-built 
SP 1098 platform. This system is yet 
to receive CE/FDA approval and re-
mains in the development stage. Two 
human pre-clinical trials have taken 
place involving five patients in R-LESS 
radical/partial nephrectomy and three 
patients in R-LESS radical perineal 
prostatectomy. Both studies conclud-
ed that R-LESS with the SP 1098 plat-
form is feasible but will require further 
investigation to compare with conven-
tional multi-port robotic surgery.
Surgibot
Surgibot was developed by TranEn-
terix (US), who upgraded on the 
SPIDER16 platform used in non-ro-
botic laparo-endoscopic single-site 
surgery by adding a robotic arm to 
control the laparoscopic instruments. 
It represents a unique system be-
cause the control resides within the 
sterile field at the patient’s bedside 
sterile field. The platform includes two 
laparoscopic handles manipulating 
two articulated instruments inserted 
through a single port. The camera is 
3D-HD ready requiring the surgeon to 
wear 3D glasses to view an open cart 
mounted monitor. The FDA rejected 
Transenterix’s Surgibot in 2016 and 
since then the company has focused 
on Asian markets by establishing 
a sales agreement with Chinese 
Great Belief International Limited for 
production and sale of the system 
in China. To date, the system does 
not have approval from the China 
Food Drug Administration and its use 
has been limited to porcine models 
in cholecystectomy.17
SPORT
The Single Port Orifice Robotic Tech-
nology surgical system (SPORT) (Fig 5) 
is developed by Titan Medical (US) 
for use in multi-quadrant R-LESS. It 
incorporates an open surgeon control 
console with 3D-HD touchscreen 
viewing monitor to control 2 articulating 
arms attached to a manoeuvrable pa-
tient cart designed for a 25mm single 
port. A unique feature is the disposable 
end effectors, which may reduce cost. 
FDA approval is awaited but pre-clin-
ical trials in single-port prostatectomy 
began in February 2018.18
Miniature in vivo robot
The miniature in vivo robot surgical 
system (MIVO) developed by Virtual 
Incision (US) and the University of 
Nebraska’s medical centre repre-
sents a unique development on pre-
viously described R-LESS systems as 
the bulk of the robotic system resides 
within the abdominal cavity during 
surgery. The system includes a cen-
tral rod attached to two triple-jointed 
robotic arms with replaceable minia-
turised end effectors capable of four 
degrees of freedom. The central rod 
is inserted through a 3.5cm incision 
and can be rotated allowing access 
to all quadrants of the abdomen. The 
advantage of this system is that the 
motor units are housed within the 
arms themselves, thereby signifi-
cantly reducing the extracorporeal 
footprint and allowing easy access 
to the patients.19 Virtual Incision will 
focus on general surgery procedures. 
Currently there is no FDA approval 
but Virtual Incision has recently 
gained funding to apply. There has 
been one human trial conducted 
Figure 4 Intuitive Surgical SP 1098 
single port articulated endoscope and 
instruments. (Image credit Rassweiler 
et al, 201725)
Figure 6 Master–Slave Transluminal 
Endoscopic Robot (MASTER) for us in 
R-NOTES. (Image credit Endomaster 
Pte Ltd)
Figure 5 Single Port Orifice Robotic 
Technology surgical system a) Open 
3D-HD workstation b) single port 
articulated endoscope and instruments. 
(Images credit Titan Medical Inc)
A
B
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in 2016 in Paraguay for a colonic 
resection to assess feasibility of the 
system and Virtual Incision plan to 
commercialise soon.
Robotic Natural Orifice 
Transluminal Endoscopic 
Surgery (R-NOTES)
NOTES demonstrates a novel ap-
proach to minimally invasive surgery – 
breaking from the traditional minimally 
invasive approach of gaining access 
to the surgical site through abdominal 
incisions and instead using the body’s 
natural orifices to enable scarless 
hernia-free surgery. The NOTES 
technique has been in development 
for many years – the first reported 
transgastric endoscopic appendicec-
tomy was performed in 2004 and the 
technique has propagated. Initially, 
the transgastric route was preferred; 
however, transvaginal, transcolonic, 
transcystic and transoesophageal 
techniques have been described with 
increasing proficiency. Similarly, the 
number of operations has increased 
to include challenging resections 
inside abdominal cavity, such as distal 
pancreatectomy via transvaginal/
transcolonic route.20 The technique 
has not been adopted as universally 
as expected and this is because of the 
extremely challenging surgical nature 
of the technique, which has prompted 
the development of robotic systems to 
shorten the learning curve (Table 2).
MASTER
The Master and Slave Transluminal 
Endoscopic Robot (Fig 6) is under 
development by Endomaster Pte 
Ltd. The system consists of a flexible 
endoscope incorporating a vide-
oscope, two robotically controlled 
effector arms with grasping and 
electrocautery function and seven 
degrees-of-freedom movement.21 A 
surgeon at the master control unit 
manipulates the haptic feedback-en-
abled end effector instruments; 
however, the endoscope requires 
human control and coordination with 
a second operator. Initial animal trials 
successfully performed endoscopic 
submucosal stomach dissection and 
transgastric hepatic wedge resec-
tion in porcine models with com-
parable operative time to traditional 
methods.21 Human trials have been 
conducted in India and Singapore on 
five patients undergoing successful 
MASTER-assisted resection of early 
gastrointestinal tumours with no 
complications and early discharge.22 
The MASTER system currently has 
no FDA/CE approval but EndoMaster 
have received Series B funding for 
further development and commer-
cialisation of the system.
Other R-NOTES/endoluminal systems
There are a number of flexible en-
doscopes with robotically controlled 
instruments including the ISIS-Scope 
(Karl Storz), Endomina (Endo Tools), 
Scorpion Shaped endoscopic robot 
(Kyushu University), and the Viacath 
system (Hansen Medical).23 Although 
the majority of these systems are 
developed for use in gastroenterology 
and thus beyond the remit of this 
review, it is likely that with improving 
R-NOTES technology the traditional 
boundaries between conventional 
resection surgery and endoluminal ap-
proaches may become less obvious.
Novel non-minimally invasive 
robotic systems
The majority of focus and publicity on 
robotic surgery has been in minimally 
invasive surgery; however, there are 
several interesting robotic devel-
opments in non-minimally invasive 
surgery-focused specialties. These 
systems are described in Table 3.
Avicenna Roboflex
A noteworthy robotic system that 
inhabits its own subcategory is the 
Avicienna Roboflex (Fig 7) for use 
in endourology. It was developed by 
Turkish company ELMED to facilitate 
robotic flexible ureterenoscopy for 
treatment of nephrolithiasis. Conven-
tional hand-operated flexible ure-
terenoscopy has some disadvantages 
for the surgeon, ie poor ergonomics 
and exposure to ionizing radiation. 
A survey of 160 endo-urologists 
found that 64.2% complained of 
orthopaedic problems, predominant-
ly relating to the back (38.1%) and 
neck (27.6%).24 The Roboflex sys-
tem includes a flexible ureteroscope 
hand-piece manipulator unit and a 
surgeon-control console with two 
joysticks to control the flexible end 
of the ureteroscope. The control unit 
has a touchscreen for adjustment of 
the laser fibre and control of irrigation 
inflow. The joystick controllers are 
ergonomically superior to convention-
al hand-unit control and the control 
console can be position far away from 
the radiation source. A human study 
of 132 patients undergoing traditional 
flexible ureterenoscopy vs robotic 
ureterenoscopy with the Roboflex 
system found comparable procedure 
time and stone-free rates.25 The 
system gained CE approval for use in 
Europe in 2013 but FDA approval is 
still pending.
Medical Microinstruments
Medical Microinstruments (MMI) 
(Fig 8) is an Italian robotic compa-
ny producing a robotic platform for 
reconstructive microsurgery. The 
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system uses 2 tiny robotic arms with 
articulated robotic wrists of 3mm in 
outer diameter and 150micron width 
robotic scissors, allowing for easy ma-
nipulation of 12.0 suture. The surgeon 
views the operating field through a 
microscope and uses a separate con-
trol unit with scaled-down tremor-free 
manipulation of the instruments. 
Preclinical work including robotic 
0.35mm vascular anastomosis has 
recently been conducted26 and it is 
expected that robotic surgery will 
enable super-microsurgery for lymph 
vessel anastomosis and micro-neuro-
surgery in the near future.27
Preceyes surgical system 
Dutch company Preceyes BV is de-
veloping the Preceyes surgical system 
(Fig 9) for use in vitreoretinal eye sur-
gery. The system gains access to the 
eye through a 1mm incision and oper-
ates at a precision level of 10 microns, 
which is far superior to that achievable 
by any unaided ophthalmologist. 
The operator views the surgical site 
through a microscope and the robotic 
joystick is placed at the patient’s 
bedside, translating and scaling 
down movements to the micron level. 
The world’s first human robotic eye 
surgery using the Preceyes system 
was performed in Oxford in 2016 and 
currently the Robotic Retinal Dissec-
tion Device Trial (NCT0305 2881) is 
underway at the University of Oxford, 
with an expected completion date 
April 2018.28 The system does not 
have CE/FDA approval.
Advances in haptic feedback
An often-cited criticism of robotic 
surgery is the lack of haptic feed-
back to the surgeon. Haptic feed-
back is described as a combination 
of force/kinaesthetic feedback and 
tactile/cutaneous feedback. Force 
feedback is useful in assessing the 
tension or pressure across tissue 
or suture, whereas tactile feedback 
provides information on local tissue 
properties such as compliance or 
viscosity. In minimally invasive sur-
gery, haptic feedback is attenuated 
owing to the long shaft of a laparo-
scopic instrument. In robotic surgery 
all haptic feedback is lost owing 
to the dissociation of surgeon to 
end effector by the robotic system. 
Studies have shown that absence 
of haptic feedback can lead to both 
excessive and inadequate forces 
being applied to tissue during robotic 
surgery, which lead to increased tis-
sue injury and inappropriate suture 
handling.29,30 
Advantages of haptic feedback
It seems intuitive that increased senso-
ry feedback should be beneficial to the 
surgeon. However, many experienced 
robotic surgeons compensate for the 
lack of haptic feedback by becoming 
highly attuned to visual cues such as 
tissue deformation to act as surro-
gates for tension and force. Ortmaier 
et al demonstrated that haptic feed-
back significantly reduced errors in a 
telerobotic dissection task.31 The study 
was corroborated by Wagner et al,32 re-
porting a significant decreased level of 
force applied to tissue and a decrease 
in number of inadvertent incursions 
into sensitive structures during a 
simulation involving a force-feedback 
enabled platform. The majority of trials 
investigating haptic feedback and 
RS are ex vivo using surgical models, 
there are just a handful of clinical trials. 
Amirabdollahian et al33 conducted a 
rigorous literature review of haptic feed-
back-mediated surgery and found only 
2 out of the 74 included studies were 
conducted on patients. One of these 
studies included the aforementioned 
haptic feedback-enabled MAKO sur-
gical system and reported increased 
accuracy of implant placement in 
unicompartmental arthroplasty.34 The 
advantages of tactile feedback, as 
opposed to force feedback, are not 
easy to quantify. A limited number of 
Figure 7 Avicenna Roboflex. Open 
robotic control console and robotic 
flexible ureterenoscope. (Image credit 
Elmed Medical Systems Inc.)
Figure 8 Robotic micro-
instrument. (Image credit Medical 
Microinstruments)
Figure 9 Preceyes microscope and 
robotic arm. (Image credit Preceyes BV) 
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studies have considered the benefit of 
tactile sensors in palpation exercises; 
for example, palpating a lung for the 
presence of a tumour35 or ‘feeling’ for 
gallstones within a gallbladder using 
laparoscopic instruments.36 The num-
ber of experimental studies assessing 
the benefit of tactile feedback is limited 
in robotic surgery and there are no 
human clinical trials published at the 
time of writing.
Current status and research
At present, the Senhance surgical 
system and MAKO RIO surgical system 
(Table 4) are the only commercially 
available surgical robotic systems 
providing haptic feedback. There have 
been no clinical studies comparing 
the benefits of haptic feedback versus 
no haptic feedback in these systems. 
The majority of robotic systems in 
development (Table 1) include haptic 
feedback and it seems this will be the 
benchmark for future systems. The 
latest da Vinci® Xi platform does not 
incorporate haptic feedback and there 
is no indication from Intuitive Surgical 
on whether future systems will include 
this feature. Several recent studies 
have made interesting modifications 
to the da Vinci® system to add haptic 
feedback functionality. Pacchieroitti 
et al37 provide tactile feedback to the 
surgeon by implanting a BiotTac tactile 
Sensor onto the effector end of the da 
Vinci® robotic laparoscopic instrument. 
The information is relayed to the sur-
geon through a custom fingertip feed-
back device mounted to a da Vinci® 
master controller providing cutaneous 
feedback to the surgeon’s index-finger 
tip. This modification significantly im-
proved task performance in a simulat-
ed palpation exercise. Mahvash et al38 
customised a da Vinci® instrument arm 
to provide direct force feedback to the 
controller and reported a significant 
improvement in palpating hardened 
nodules in soft-tissue models. 
Sensory substitution 
In order to avoid the difficulties en-
countered in relaying force and tactile 
information directly to the surgeon’s 
hands, many studies have focused 
on ‘sensory substitution’ providing 
haptic information though auditory 
or graphical cues.39 Reilly et al40 
evaluated the benefit of employing 
visual force feedback (VFF) on robotic 
surgical knot tying using a da Vinci® 
robotic system. Strain gauges were 
implemented into the instruments to 
measure bending forces and a graph-
ical overlay displayed ideal suture 
tension in a non-intrusive manner. 
The study reported significantly fewer 
suture breakages and lower peak 
force across suture with VFF.
Virtual fixtures
An interesting application of haptic 
feedback is the creation of ‘virtual 
fixtures’ using software to create 
‘no-go’ areas and preventing robotic 
instruments from entering into sen-
sitive tissue. The MAKO RIO system 
uses virtual fixtures to enable milling 
of bone to a preoperative plan and 
disables milling outside of pre-set 
System Developer Special Features Clinical Use
Da Vinci® Xi 4th 
generation
Intuitive Surgical 
(Sunnyvale, US)
4 arms on single cart, 8mm 
instruments, finger-tip control 
endo-wrist with 7 d.o.f, closed 
3D-HD console
Minimally invasive 
surgery
FDA/CE approved
Worldwide use
Mako RIO surgical 
system
Stryker 
orthopaedics 
(Kalamazoo, US)
Haptic feedback, single cart 
robotic arm, milling device
Orthopaedics, FDA 
approval for hip and 
partial/total knee 
arthroplasty in 2008
Navio surgical 
system
Smith and 
Nephew (US)
Handheld semi-active 
handheld device, guides 
milling based on preoperative 
imaging, live tracking 
Orthopaedics, FDA 
approval 2012 for 
total and partial knee 
arthroplasty
Mazor 
Renaissance
Mazor Robotics 
(Israel)
CT image analysis with 
fluoroscopic registration, 
mounted guide for 1.5mm 
precision of intervention
Orthopaedics, FDA 
approval 2011
Sensei X robotic 
system
Hansen Medical 
(US)
Remote workstation, Mechanically 
driven catheter delivery
Cardiac intervention, 
FDA approval 2007
Niobe Magnetic 
Navigation system
Sterotaxis (USA) Remote work station, 
magnetically driven  
catheter delivery
Cardiac intervention, 
FDA approval 2003
Amigo Remote 
Catheter system
Catheter Robotics Remote control, mechanically 
driven catheter delivery
Cardiac intervention, 
FDA approval 2012
Magellan Robotic 
system
Hansen medical  
(US)
Remote workstation, 
mechanically driven  
catheter delivery
Peripheral vascular 
intervention, FDA 
approval 2012
Corpath 200 
System
Corindus Vascular 
Robotics
Remote workstation, 
mechanically driven  
catheter delivery
Cardiac intervention, 
FDA Approval 2012
Table 4 Currently commercially available robotic systems
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boundaries. Such an application could 
easily be applied to minimally invasive 
surgery to avoid inadvertent injury 
to major vessels or adjacent organs. 
One recent study conducted resection 
of glioma in 18 patients using the 
NeuroArm robot and reported that the 
creation of a surgical corridor using 
virtual fixtures increased the safety 
and performance of the operation.41
It is problematic to add haptic feedback 
to an existing robotic system owing to 
issues with size, weight, biocompati-
bility, sterility and cost. Thus if the da 
Vinci® system is to gain haptic feed-
back it will require significant re-design 
of the robotic arms and control system. 
There is intense research focus in this 
area, which is beginning to translate 
into clinical practice with novel systems 
adopting force feedback. The future 
role of tactile feedback is difficult to 
assess, given that the research is still in 
its infancy and the technical difficulty of 
adding a tactile sensor to an instrument 
without diminishing its functionality. 
Haptic feedback is an area where Intui-
tive Surgical’s rivals may gain a compet-
itive advantage in the surgical robotics 
market and it is likely to represent the 
‘gold standard’ in future robotic surgery.
Advances in nanorobotics
Nanotechnology is a rapidly devel-
oping field in medicine and surgery 
with huge potential. Owing to the 
recent realisation of several techno-
logical milestones, it is anticipated 
that nanotechnology will in the not too 
distant future translate from research 
into clinical practice. Nanorobotics 
relate to synthetic devices in the size 
range of 1 to 100nm and microrobotics 
are those sub-1mm in size. For point 
of reference, a strand of DNA is 2nm 
wide and a red blood cell is 7,000nm 
wide.42 Although many of the robotic 
systems described earlier comprise 
large complex rigid devices with in-
vasive patient-robot interface, nano-
technology provides the opportunity to 
operate at the cellular level with greater 
precision, efficiency and with unfet-
tered access to all organ systems. This 
review will focus specifically on nano-
robotics in surgery and will not provide 
a general overview of nanotechnology 
because the subject is too vast.
Nanorobotic challenges
In order to reach a level of research 
maturity whereby nanotechnology can 
be used in clinical practice, several 
technological milestones have been 
achieved and these will be outlined 
first before going on to discuss future 
applications. To reach target sites and 
navigate the human body, nanorobots 
need efficient propulsion mechanisms 
capable of traversing large blood ves-
sels, capillaries and intra-cellular com-
partments. Many strategies have been 
developed involving micromotors that 
create the energy-required ether from 
local chemical substrates or external 
sources such as magnetic, ultrasound, 
thermal and electrical energy. Solovev 
et al43 describe a microtubule con-
taining a catalyst for chemical fuel to 
self-propel through air bubble ejection 
similar to a ‘microjet’ and capable of 
speeds of 2 micrometres per second. 
Ghosh et al44 describe the creation 
of 200nm-wide nanopropellors, akin 
to bacterial flagella, powered and 
directed by externally applied magnet-
ic fields. Martel provides an excellent 
review on the benefits of coupling 
nanotechnology with natural microor-
ganisms, harnessing certain bacteria’s 
innate propulsion mechanism and 
negating the need for development of 
novel locomotive strategies.45
After power and locomotion, the 
second challenge with regard to de-
velopment of nanorobots is the ability 
to control and direct the nanorobots 
within the human body. Early work 
by Weibel et al46 described a novel ex 
vivo method of nanorobot control by 
combing polystyrene beads to a flag-
ellated algae and inducing directional 
movement via phototaxis from an LED 
light source. The first description of 
in vivo directional controlled objects 
involved the manipulation of a 1.5mm 
chrome sphere within the carotid 
artery of a live pig, achieving peak ve-
locity speeds of up to 11.1cm/s. This 
study used a conventional magnetic 
resonance imaging (MRI) scanner 
found in many radiology departments 
and represented a shift towards the 
currently used MRI-based navigation-
al systems.47 More recently, Octomag 
(an electromagnetic navigation sys-
tem) was used to direct a microrobot 
to puncture the retinal vessels of a 
chicken embryo.48 A possible appli-
cation for this system is in retinal vein 
cannulation and injection of thrombol-
ysis for retinal vein occlusion.
The development of tiny self-propelling 
robots capable of harvesting energy 
from their surroundings or from exter-
nal energy sources has given the sci-
entific community a glimpse of future 
therapeutic opportunities. The next part 
of the review will detail future clinical 
applications of nanorobots in surgery.
Nanosurgery
It is not inconceivable that within our 
lifetime nanorobots will be able to enter 
the human body through injection into 
vessels, target a particular site either 
autonomously or surgeon-controlled, 
manipulate pathological tissue with 
nano-instruments, and feed back 
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information to the surgeon before 
biodegrading without a trace. Many 
of the necessary nanometre-sized 
surgical instruments have already been 
produced. Kirson et al49 describe a 
vibrating micropipette less than a mi-
crometre in diameter used to cleave off 
denrites from their neuronal cell bodies 
without damaging the cell. Leong et 
al50 detail the fabrication of unteth-
ered ‘micrograbbers’ that are remotely 
triggered in response to temperature or 
chemicals and are capable of captur-
ing tissue from hard-to-reach areas 
for use in biopsy, for example. Kagan 
et al51 describe ultrasound-triggered 
ballistic missile-like nanorobots that 
are capable of damaging pathological 
tissue by penetrating deep into it at 
impressive speeds of up to six metres 
per second. On an even smaller scale, 
Srivastava discusses ‘microdiggers’ that 
drill into individual target cells thereby 
allowing for highly specific single-cell 
surgery.52 Analogous to the advance-
ments seen in conventional surgery 
with the development of increasingly 
specialised surgical instruments, these 
nano-instruments will enable exciting 
developments in nanosurgery.
Targeted oncological therapy
A disadvantage of systemic chemo-
therapy is global toxicity damaging 
healthy non-cancerous cells and lim-
iting the therapeutic dose that can be 
given. Nanorobots have the potential 
to target cancerous cells and release 
chemotherapeutic drug ‘pay-loads’ 
providing targeted therapy. Balasubra-
manian et al53 developed a self-pro-
pelling nanorobot with a functional 
cancer-specific antibody unit able to 
search out and bind to pancreatic 
cancer cells in vitro. Pouponneau 
et al54 conducted the first in vivo 
pre-clinical study involving rabbits as 
a model for treatment of hepatocellu-
lar carcinoma. They demonstrated the 
ability to steer nanorobots to a specific 
area within the liver using magnetic 
resonance navigation, followed by 
selective embolisation of hepatic 
vasculature and deposition of chem-
otherapeutic doxorubicin within the 
hepatic tissue. More recently in 2018, 
Li et al55 described an in vivo study 
demonstrating autonomous deposition 
of thrombin by a DNA nanorobot in 
response to a tumour vessel marker. 
This process facilitated chemo-em-
bolisation, which lead to increased 
survival, tumour size reduction 
and decreased metastasis in mice 
melanoma models. It is postulated 
that nanorobots have the potential to 
deliver more than just drugs to cancer 
cells and may in the future target 
tumour cells with brachytherapy, 
stem cells or even heat in the form of 
thermo-ablative therapy.56
Many of the described studies so far 
include in vitro proof-of-concept re-
search and, although it is easy to get 
carried away with another ‘Holy Grail’ 
medical innovation, there are current-
ly no human clinical trials involving 
nanorobots. Thus, it remains to be 
seen whether nanrobotics can fulfil its 
promising potential.
Conclusion
Throughout the past two decades, 
there has been tremendous change 
with the advent and proliferation of 
robotic surgery. In the field of minimal-
ly invasive surgery, this landscape has 
been dominated by one platform, ie 
Intuitive Surgical’s da Vinci® surgi-
cal system. This review has outlined 
the current status of robotic surgery 
and provided detailed description of 
currently commercially available and 
novel robotic systems in development. 
These future systems may shift the 
current paradigm to create a more 
competitive market, leading to a sub-
sequent decrease in cost and greater 
availability of robotic surgery to all. The 
impact on training and comparative 
research with the likely increased 
uptake of a variety of heterogeneous 
robotic systems is difficult to assess 
at present. However, it seems improb-
able that robotic manufactures will 
co-operate with each other to stand-
ardise certain aspects of their systems, 
given what is at stake commercially. 
Despite these challenges, the develop-
ment and proliferation of novel robotic 
systems pushes the boundaries of 
what is possible with robotic surgery.
This review details the current advanc-
es in haptic feedback, which is a field 
on the verge of translating from the re-
search arena into clinical practice and 
consequently physically re-connecting 
robotic surgeons with their patients 
to the benefit of both. In contrast, 
nanotechnology remains firmly in the 
experimental stage, with promising ear-
ly proof-of-concept studies but little in 
the way of rigorous Level 1 evidence. It 
will be interesting to see how this novel 
technology adapts and propagates, as 
it draws parallels with the birth of ro-
botic surgery in the ideals it promotes, 
ie better surgical outcome through 
miniaturisation, increased autonomy 
and reduced patient intrusiveness. 
Whatever the future holds, it is certain 
that robotic surgery will continue to 
play an important role.
Robotics: Annals of the Royal College of Surgeons of England 
References
1. Rassweiler JJ, Autorino R, Klein J et al. 
Future of robotic surgery in urology. BJU Int 
2017; 120: 822–841.
2. Bozzini G, Gidaro S, Taverna G. Robot-
assisted laparoscopic partial nephrectomy 
with the ALF-X robot on pig models. Eur Urol 
2016; 69(2): 376–377.
3. Spinelli A, David G, Gidaro S et al. First 
Experience in Colorectal Surgery with a new 
Robotic Platform with Haptic Feedback. 
Colorectal Dis 2017 Sep 14. doi: 10.1111/
codi.13882
4. Gueli Alletti S, Rossitto C, Cianci S et al. 
The Senhance™ surgical robotic system 
(“Senhance”) for total hysterectomy in obese 
patients: a pilot study. J Robot Surg 2017 
June 17. doi: 10.1007/s11701-017-0718-9
5. Lococo A, Larocca V, Marino F et al. 
experimental robotic pulmonary lobectomy 
with the TELELAP/ALFX system in the ovine 
model. Surg Innov 2015; 22: 252–256.
6. CMR Surgical. Press kit 2017. https://
cmrsurgical.com/press-kit/ (cited April 2018).
7. Hagn U, Konietschke R, Tobergte A et 
al. DLR MiroSurge: a versatile system for 
research in endoscopic telesurgery. Int 
J Comput Assist Radiol Surg 2010; 5: 
183–193.
8. Konietschke R, Hagn U, Nickl M et al. 
The DLR MiroSurge – A Robotic System 
for Surgery. 2009 IEEE International 
Conference on Robotics and Automation 
Kobe International Conference Center Kobe, 
Japan, 2009. http://www.robotic.de/fileadmin/
robotic/konietschke/Publications/ICRA_2009_
Abstract_Konietschke_Miro_0477_
CameraReady.pdf (cited April 2018).
9. Konietschke R, Knoferle A, Hirzinger G. 
The AutoPointer: ‘A new augmented-reality 
device for transfer of planning data into the 
operating room’. In Proceedings of the 21st 
International Congress and Exhibition of 
Computer Assisted Radiology and Surgery 
(CARS). Berlin, Germany.2007.
10. Rao PP. Robotic surgery: new robots and 
finally some real competition! World J Urol 
2018; 36: 537–541. 
11. Lim JH, Woo Jung Lee WJ, Dong Won 
Park DW et al. Robotic cholecystectomy 
using Revo-i Model MSR–5000, the newly 
developed Korean robotic surgical system: 
a preclinical study. Surg Endosc 2017; 31: 
3,391–3,397.
12. Khateeb OM. Democratizing Surgery Part 1: 
What Verb Surgical Is Creating. https://www.
linkedin.com/pulse/democratizing-surgery-
how-verb-surgical-invented-new-category 
(cited April 2018).
13. Henry B, Glenn Novarro G. Peering Behind 
The Veil of Secrecy In Surgical Robotics & 
2016 Market Outlook. www.rbcinsight.com/
WM/Share/ResearchViewer/?SSS_52256 
1613B1ADBDE80B721B19D8A2330 
 (cited April 2018).
14. Nelson RJ,  Sai J, Chavali S et al. Current 
status of robotic single-port surgery. Urol Ann 
2017; 9: 217–222.
15. Haber GP, White MA, Autorino R et al. 
Novel robotic da Vinci instruments for 
laparoendoscopic single-site surgery. Urology 
2010; 76: 1,279–1,282.
16. Ramirez D, Maurice M, Kaou JH. Robotic 
perineal radical prostatectomy and pelvic 
lymph node dissection using a purpose-built 
single-port robotic platform. BJU Int 2016; 
118: 829–833.
17. Pryor AD, Tushar JR, DiBernardo LR. Single-
port cholecystectomy with the TransEnterix 
SPIDER: simple and safe. Surg Endosc 2010; 
24: 917–923.
18. Peters BS, Armijo PR, Krause C et al. Review 
of emerging surgical robotic technology. Surg 
Endosc 2018; 32: 1,636–1,655.
19. Titan Medical. World’s first single-port 
prostatectomy using Titan Medical’s Surgical 
system completed in pre–clinical setting. 
February 2018. https://titanmedicalinc.
com/worlds-first-single-port-prostatectomy-
using-titan-medicals-sport-surgical-system-
completed-preclinical-setting/ (cited April 
2018).
20. Wortman TD. Design, analysis, and testing 
of in vivo surgical robots. Department of 
Mechanical Engineering, University of 
Nebraska. 2010. https://digitalcommons.unl.
edu/cgi/viewcontent.cgi?referer=https://www.
google.co.uk/&httpsredir=1&article=1029& 
context=mechengdiss (cited April 2018).
21. Ryou M, Fong DG, Pai RD et al. Dual-port 
distal pancreatectomy using a prototype 
endoscope and endoscopic stapler: a natural 
orifice transluminal endoscopic surgery 
(NOTES) survival study in a porcine model. 
Endoscopy 2007; 10: 881–887.
22. Sun Z, Ang RY, Lim EW et al. Enhancement 
of a masterslave robotic system for natural 
orifice transluminal endoscopic surgery. Ann 
Acad Med Singapore 2011; 40: 223–230.
23. Phee SJ, Reddy N, Chiu PW et al. Robot-
assisted endoscopic submucosal dissection 
is effective in treating patients with early-stage 
gastric neoplasia. Clin Gastroenterol Hepatol 
2012; 10: 1,117–1,121.
24. Po B, Yeung M, Wai P Chiu Y. Application 
of robotics in gastrointestinal endoscopy: 
A review. World J Gastroenterol 2016; 22: 
1,811–1,825.
25. Elkoushy MA, Andonian S. Prevalence of 
orthopedic complaints among endourologists 
and their compliance with radiation safety 
measures. J Endourol 2011; 25: 1,609–
1,613.
26. Geavlete P, Saglam R, Georgescu D et al. 
Robotic flexible ureteroscopy versus classic 
flexible ureteroscopy in renal stones: the 
initial Romanian experience. Chirurgia 
(Bucur) 2016; 111; 326–329.
27. Innocenti M. A New Robotic Platform 
Devoted to Microsurgery: Preliminary Report. 
Podium presentation at Congress of World 
Society for Reconstructive Microsurgery. Italy, 
2016.
28. Struk S, Qassemyar Q, Leymarie N et al. The 
ongoing emergence of robotics in plastic and 
reconstructive surgery. Ann Chir Plast Esthet 
2018; 63: 105–112.
29. Clinicaltrial.gov. Robotic Retinal Dissection 
Device Trial. https://clinicaltrials.gov/ct2/show/
NCT03052881 (cited April 2018).
30. Akinbiyi T, Reiley CE, Saha S et al. Dynamic 
augmented reality for sensory substitution in 
robot-assisted surgical systems. Conf Proc 
IEEE Eng Med Biol Soc 2006; 1: 567–570. 
31. Okamura AM. Haptic feedback in robot-
assisted minimally invasive surgery. Curr Opin 
Urol 2009; 19: 102–107.
32. Ortmaier T, Deml B, Kuebler B et al. Robot-
assisted force feedback surgery. In: Ferre M, 
Buss M, Aracil R et al, editors. Advances in 
Telerobotics, Springer Tracts in Advanced 
Robotics (STAR) Vol. 31. New York: Springer; 
2007. pp. 341–358.
33. Wagner CR, Stylopoulos N, Jackson PG, 
Howe RD. The benefit of force feedback in 
surgery: examination of blunt dissection. 
Presence: Teleoperators Virtual Environ 2007; 
16: 252–262.
34. Amirabdollahian F, Livatino S, Vahedi B et 
al. Prevalence of haptic feedback in robot-
mediated surgery: a systematic review of 
literature. J Robot Surg 2018; 12: 11–25.
 Future of robotic surgery
35. Roche M. Robotic-assisted unicompartmental 
knee arthroplasty: The MAKO experience. 
Clin Sports Med 2014; 33: 123–132.
36. Eltaib MEH, Hewit JR. Tactile sensing 
technology for minimal access surgery –a 
review. Mechatronics 2003; 13: 1,163–
1,177.
37. Matsumoto S, Ooshima R, Kobayashi K 
et al. A tactile sensor for laparoscopic 
cholecystectomy. Surg Endosc 1997; 11(9): 
939–941.
38. Pacchierotti C, Prattichizzo D, Kuchenbecker 
KJ. Cutaneous feedback of fingertip 
deformation and vibration for palpation in 
robotic surgery. IEEE Trans Biomed Eng 
2015; 63(2): 278–287.
39. Mohsen M, Gwilliam J, Agarwal R et al. 
Force-feedback surgical teleoperator: 
controller design and palpation experiment. 
Conference: Haptic Interfaces For Virtual 
Environment And Teleoperator Systems, 
2008. Symposium on Haptics, 2008. https://
www.researchgate.net/publication/4325116_
Force-Feedback_Surgical_Teleoperator_
Controller_Design_and_Palpation_
Experiments (cited April 2018).
40. Kitagawa M, Dokko D, Okamura AM, Yuh 
DD. Effect of sensory substitution on suture 
manipulation forces for robotic surgical 
systems. J Thorac Cardiovasc Surg 2005; 
129: 151–158.
41. Reiley CE, Akinbiyi T, Burschka D, Chang 
D, Okamura A, Yuh D. Effects of visual force 
feedback on robot-assisted surgical task 
performance. J Thorac Cardiovasc Surg 
2008; 135: 196–202.
42. Sutherland GR, Maddahi Y, Gan LS et al. 
Robotics in the neurosurgical treatment of 
glioma. Surg Neurol Int 2015; 6: S1–S8.
43. Saadeh Y, Dinesh Vyas D. Nanorobotic 
applications in medicine: current proposals 
and designs. Am J Robot Surg 2014; 1: 
4–11.
44. Solovev AA, Mei Y, Bermúdez Ureña E et 
al. Catalytic microtubular jet engines self–
propelled by accumulated gas bubbles. Small 
2009; 5: 1,688–1,692.
45. Ghosh A, Fischer P. Controlled propulsion of 
artificial magnetic nanostructured propellers. 
Nano Lett 2009; 9: 2,243–2,245.
46. Martel S. Swimming microorganisms acting 
as nanorobots versus artificial nanorobotic 
agents: A perspective view from an historical 
retrospective on the future of medical 
nanorobotics in the largest known three-
dimensional biomicrofluidic networks. 
Biomicrofluidics 2016; 10: 021301.
47. Weibel DB, Garstecki P, Ryan D et al. 
Microoxen: Microorganisms to move 
microscale loads. National Acad Sciences 
2005; 102: 11,963–11,967.
48. Martel S, Mathieu J-B, Felfoul O et al. 
Automatic navigation of an untethered 
device in the artery of a living animal using 
a conventional clinical magnetic resonance 
imaging system. Appl Phys Lett 2007; 90: 
1141105. https://doi.org/10.1063/1.2713229
49. Kummer MP, Abbott J, Kratochvil BE et 
al. OctoMag: An electromagnetic system 
for 5-DOF wireless micromanipulation. 
IEEE Transactions on Robotics 2010; 26: 
1,006–1,017.
50. Kirson ED, Yaari Y. A novel technique for 
microdissection of neuronal processes. J 
Neurosci Methods 2000; 98: 119–122.
51. Leong TG, Randall CL, Benson BR et al..
Tetherless thermobiochemically actuated 
microgrippers. Proc Natl Acad Sci U S A 
2009; 106: 703–708.
52. Kagan D, Benchimol MJ, Claussen JC et al. 
Acoustic droplet vaporization and propulsion 
of perfluorocarbon–loaded microbullets for 
targeted tissue penetration and deformation. 
Angew Chem Int Ed Engl 2012; 51: 
7,519–7,522.
53. Srivastava SK, Medina-Sánchez M, Koch 
B et al. Medibots: dual-action biogenic 
microdaggers for single-cell surgery and drug 
release. Adv Mat 2016; 28: 832–837.
54. Balasubramanian S, Kagan D, Hu CM et al. 
Micromachine-enabled capture and isolation 
of cancer cells in complex media. Angew 
Chem Int Ed Engl 2011; 50: 4,161–4,164.
55. Pouponneau P, Leroux JC, Soulez G et al. 
Co-encapsulation of magnetic nanoparticles 
and doxorubicin into biodegradable 
microcarriers for deep tissue targeting by 
vascular MRI navigation. Biomaterials 2011; 
32: 3,481–3,486.
56. Li S. A DNA nanorobot functions as a cancer 
therapeutic in response to a molecular 
trigger in vivo. Nature Biotechnol 2018; 36: 
258–364.
57. Nelson BJ, Kaliakatsos IK, Abbott JJ. 
Microrobots for Minimally Invasive Medicine. 
Annu Rev Biomed Eng 2010; 12: 55–85.
